Invion’s (ASX:IVX) research partner to present Photosoft™ technology at ComBio2022

Be the First to Comment Read
Sponsored

Invion’s (ASX:IVX) research partner to present Photosoft™ technology at ComBio2022

Follow us on Google News:
 Invion’s (ASX:IVX) research partner to present Photosoft™ technology at ComBio2022
Image source: © Rawpixelimages | Megapixl.com

Highlights

  • Invion’s research partner Hudson Institute is set to present PhotosoftTM technology at the renowned ComBio2022 industry conference.
  • ComBio is a national conference featuring renowned international speakers.
  • In the presentation, Hudson Institute will compare a PhotosoftTM compound with two other chlorin-based photosensitisers, including Talaporfin sodium.

Invion Limited (ASX: IVX) has provided an update concerning its PhotosoftTM technology, under development for the treatment of various cancers.

The life-science company has announced that its research partner Hudson Institute of Medical Research will present a poster on PhotosoftTM technology at the renowned ComBio2022 industry conference. The conference will take place in Melbourne during 27-30 September 2022.

Invion is pursuing the development of PhotosoftTM technology as a novel next-generation Photodynamic Therapy (PDT), which selectively kills cancer cells and promotes an anti-cancer immune response by leveraging non-toxic photosensitisers and light.

ComBio is the national conference of the Australian Society for Biochemistry and Molecular Biology (ASBMB). The conference takes place on a biannual basis, runs in conjunction with other societies, and features renowned international speakers.

In the poster presentation, Hudson Institute will compare a PhotosoftTM compound with two other chlorin-based photosensitisers, including Talaporfin sodium. Talaporfin has received approval in Japan for the treatment of lung cancer.

The poster will highlight the major findings from studies in phyllochlorin sodium in in vitro and in vivo conditions. Phyllochlorin sodium is a compound that belongs to a new group of chlorin-based photosensitisers within the PhotosoftTM technology suite.

The research of Hudson Institute provides an understanding of the development of a novel family of photosensitisers based on the PhotosoftTM technology and their potential clinical efficiency and usage for Photodynamic Therapies.

Data and image source: IVX update
© 2022 Kalkine Media®

IVX shares were trading at AU$0.013 early morning on 28 September 2022.

Disclaimer

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK